{"gene":"TM4SF20","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":2014,"finding":"TM4SF20 normally inhibits regulated intramembrane proteolysis (RIP) of the membrane-bound transcription factor CREB3L1; TGF-β stimulates collagen synthesis by inhibiting TM4SF20 expression, thereby releasing this inhibition and allowing CREB3L1 cleavage and nuclear entry.","method":"Loss-of-function and expression studies in human A549 cells; proteolytic activation assays of CREB3L1","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (expression knockdown, proteolysis assay, nuclear translocation) demonstrating TM4SF20 as inhibitor of CREB3L1 RIP","pmids":["25310401"],"is_preprint":false},{"year":2013,"finding":"A 4 kb deletion removing exon 3 of TM4SF20 introduces a premature stop codon, producing a truncated protein that fails to target to the plasma membrane and instead accumulates in the cytoplasm, indicating that proper membrane targeting is required for TM4SF20 function.","method":"Minigene analysis, subcellular localization studies of truncated vs. wild-type TM4SF20","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization experiment with functional implication, single lab","pmids":["23810381"],"is_preprint":false},{"year":2016,"finding":"Ceramide inverts the membrane topology of TM4SF20 by altering the translocation direction of its first transmembrane helix during translation (Regulated Alternative Translocation, RAT): in the absence of ceramide, the N terminus is translocated into the ER lumen (requiring TRAM2); in the presence of ceramide, the N terminus remains cytosolic in a TRAM2-independent manner. This topological inversion converts TM4SF20 from an inhibitor to an activator of CREB3L1 cleavage.","method":"Topology mapping assays, co-immunoprecipitation with TRAM2, ceramide treatment, TRAM2 knockdown, functional assays of CREB3L1 cleavage","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1-2 — reconstitution of topological inversion with multiple orthogonal methods (topology assay, KD of TRAM2, ceramide treatment, protease cleavage readout), published in high-impact journal","pmids":["27499293"],"is_preprint":false},{"year":2019,"finding":"Site-directed mutagenesis identified specific residues in the first transmembrane helix of TM4SF20 required for ceramide-induced RAT: Asn-26 in the GXXXN motif is essential and cannot be substituted even by Gln; Gly-22 can be replaced by Ala or Ser; Pro-29 together with Leu-25 or Val-17 form an additional critical surface. These residues are predicted to lie along the same face of the transmembrane helix, suggesting interactions with other proteins during translocation mediate RAT.","method":"Site-directed mutagenesis, TM4SF40-TM4SF20 chimera analysis, topology assays, functional CREB3L1 cleavage assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis with chimera analysis and functional readout, multiple residues identified","pmids":["30808712"],"is_preprint":false},{"year":2023,"finding":"TM4SF20 is synthesized in the ER with a cytosolic C terminus and a luminal loop before the last transmembrane helix that is N-glycosylated at N132, N148, and N163. In the absence of ceramide, the sequence surrounding glycosylated N163 undergoes retrotranslocation from ER lumen to cytosol (independent of ERAD), relocating the C terminus from cytosol to lumen. Ceramide delays this retrotranslocation, causing accumulation of the originally synthesized (non-retrotranslocated) form.","method":"N-glycosylation mapping, topology assays, ERAD inhibition, ceramide treatment, biochemical fractionation","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal biochemical methods (glycosylation mapping, topology assay, ERAD independence) in a single rigorous study","pmids":["36972171"],"is_preprint":false},{"year":2021,"finding":"Ceramide-induced RAT of TM4SF20 is crucial for the effectiveness of doxorubicin-based chemotherapy, establishing a physiological role for TM4SF20 topological regulation in the cellular response to this chemotherapeutic agent.","method":"Cell-based chemotherapy response assays with RAT-deficient TM4SF20 mutants","journal":"Advances in experimental medicine and biology","confidence":"Medium","confidence_rationale":"Tier 2 — functional loss-of-function with defined phenotypic readout, but reported in a review context with limited methodological detail","pmids":["32986129"],"is_preprint":false}],"current_model":"TM4SF20 is a polytopic ER membrane protein whose topology is dynamically regulated by ceramide through Regulated Alternative Translocation (RAT): in the absence of ceramide, TRAM2-dependent translocation of its first transmembrane helix places the N terminus in the ER lumen, and subsequent retrotranslocation of a glycosylated luminal loop (around N163) further remodels topology; ceramide blocks both processes, inverting TM4SF20 topology and converting it from an inhibitor to an activator of CREB3L1 regulated intramembrane proteolysis, thereby controlling collagen synthesis and cellular responses to chemotherapy."},"narrative":{"teleology":[{"year":2013,"claim":"It was unknown whether TM4SF20 required intact membrane targeting for function; a disease-associated exon 3 deletion was shown to produce a truncated protein that mislocalizes to the cytoplasm, establishing that proper membrane insertion is essential.","evidence":"Minigene analysis and subcellular localization of truncated vs. wild-type TM4SF20 in transfected cells","pmids":["23810381"],"confidence":"Medium","gaps":["Single-lab observation without independent replication","Whether cytoplasmic accumulation causes a dominant-negative effect or simple loss of function was not determined","Downstream cellular consequences of mislocalization were not characterized"]},{"year":2014,"claim":"The molecular function of TM4SF20 was unknown; loss-of-function and expression studies revealed that TM4SF20 normally inhibits regulated intramembrane proteolysis of CREB3L1, and TGF-β stimulates collagen synthesis by downregulating TM4SF20 to release this inhibition.","evidence":"Knockdown, overexpression, CREB3L1 proteolytic activation, and nuclear translocation assays in A549 cells","pmids":["25310401"],"confidence":"High","gaps":["The mechanism by which TM4SF20 inhibits CREB3L1 cleavage (direct interaction vs. indirect) was not resolved","Whether CREB3L1 is the sole downstream target was not tested"]},{"year":2016,"claim":"How ceramide signaling could toggle TM4SF20 activity was unknown; topology mapping and TRAM2 dependence experiments demonstrated that ceramide inverts TM4SF20 membrane topology via Regulated Alternative Translocation (RAT), converting it from an inhibitor to an activator of CREB3L1 cleavage.","evidence":"Topology mapping, co-immunoprecipitation with TRAM2, TRAM2 knockdown, and ceramide treatment with CREB3L1 cleavage readout","pmids":["27499293"],"confidence":"High","gaps":["How ceramide is sensed at the translocon to alter translocation directionality was not identified","Whether other lipids can similarly trigger RAT was not explored"]},{"year":2019,"claim":"The structural determinants within TM4SF20 that sense ceramide during RAT were unknown; systematic mutagenesis identified Asn-26 in a GXXXN motif and an adjacent Pro-29/Leu-25/Val-17 surface on the first transmembrane helix as essential for ceramide-responsive topology inversion.","evidence":"Site-directed mutagenesis, TM4SF20-TM4SF40 chimera swaps, topology and CREB3L1 cleavage assays","pmids":["30808712"],"confidence":"High","gaps":["The translocon-side partner that reads these residues during RAT is unidentified","No structural model of the TM1–translocon interaction exists","Whether these residues directly contact ceramide or a ceramide-modified protein is unknown"]},{"year":2021,"claim":"Whether RAT of TM4SF20 had physiological consequences beyond collagen regulation was unclear; RAT-deficient mutants showed that ceramide-induced topology switching is required for doxorubicin chemosensitivity.","evidence":"Cell-based chemotherapy response assays with RAT-deficient TM4SF20 mutants","pmids":["32986129"],"confidence":"Medium","gaps":["Limited methodological detail in the reporting context","In vivo validation of the chemotherapy connection is lacking","Whether RAT affects sensitivity to other ceramide-generating chemotherapeutics is untested"]},{"year":2023,"claim":"Post-translational topology remodeling of TM4SF20 beyond initial RAT was uncharacterized; glycosylation mapping revealed that a luminal loop glycosylated at N132/N148/N163 undergoes ERAD-independent retrotranslocation to the cytosol, and ceramide delays this second topology rearrangement.","evidence":"N-glycosylation site mapping, topology assays, ERAD inhibitor controls, ceramide treatment, biochemical fractionation","pmids":["36972171"],"confidence":"High","gaps":["The machinery mediating ERAD-independent retrotranslocation is unidentified","Whether retrotranslocation is required for the inhibitory function of TM4SF20 has not been directly tested","The fate of the deglycosylated retrotranslocated loop is unknown"]},{"year":null,"claim":"The identity of the translocon component(s) that read ceramide levels and the TM1 GXXXN motif to execute RAT, and the structural basis of TM4SF20's dual topology, remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No cryo-EM or crosslinking-MS structure of TM4SF20 at the translocon","Direct ceramide-binding partner at the translocon not identified","In vivo physiological roles beyond cell-based assays not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,2]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[2,4]}],"pathway":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0]}],"complexes":[],"partners":["CREB3L1","TRAM2"],"other_free_text":[]},"mechanistic_narrative":"TM4SF20 is an ER-resident polytopic membrane protein that functions as a ceramide-responsive switch controlling regulated intramembrane proteolysis (RIP) of the transcription factor CREB3L1, thereby linking lipid signaling to collagen synthesis and chemotherapy responses. In the absence of ceramide, TM4SF20 adopts a TRAM2-dependent topology with its N terminus translocated into the ER lumen and undergoes post-translational retrotranslocation of a glycosylated luminal loop (N163 region), functioning as an inhibitor of CREB3L1 cleavage; TGF-β promotes collagen synthesis by downregulating TM4SF20 expression and relieving this inhibition [PMID:25310401, PMID:36972171]. Ceramide inverts TM4SF20 membrane topology through Regulated Alternative Translocation (RAT) of its first transmembrane helix—dependent on a critical GXXXN motif residue Asn-26—converting TM4SF20 from an inhibitor to an activator of CREB3L1 proteolytic activation, a mechanism also required for doxorubicin chemosensitivity [PMID:27499293, PMID:30808712, PMID:32986129]. Loss of exon 3 produces a truncated protein that fails to reach the membrane and accumulates in the cytoplasm, linking TM4SF20 to a language delay phenotype in affected families [PMID:23810381]."},"prefetch_data":{"uniprot":{"accession":"Q53R12","full_name":"Transmembrane 4 L6 family member 20","aliases":[],"length_aa":229,"mass_kda":25.1,"function":"Polytopic transmembrane protein that inhibits regulated intramembrane proteolysis (RIP) of CREB3L1, inhibiting its activation and the induction of collagen synthesis (PubMed:25310401, PubMed:27499293). In response to ceramide, which alters TM4SF20 membrane topology, stimulates RIP activation of CREB3L1 (PubMed:27499293). Ceramide reverses the direction through which transmembrane helices are translocated into the endoplasmic reticulum membrane during translation of TM4SF20, this mechanism is called 'regulated alternative translocation' (RAT) and regulates the function of the transmembrane protein (PubMed:27499293)","subcellular_location":"Membrane; Endoplasmic reticulum membrane","url":"https://www.uniprot.org/uniprotkb/Q53R12/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TM4SF20","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TM4SF20","total_profiled":1310},"omim":[{"mim_id":"619773","title":"IMMUNODEFICIENCY 95; IMD95","url":"https://www.omim.org/entry/619773"},{"mim_id":"615432","title":"SPECIFIC LANGUAGE IMPAIRMENT 5; SLI5","url":"https://www.omim.org/entry/615432"},{"mim_id":"615404","title":"TRANSMEMBRANE 4 L6 FAMILY, MEMBER 20; TM4SF20","url":"https://www.omim.org/entry/615404"},{"mim_id":"606951","title":"INTERFERON-INDUCED HELICASE C DOMAIN-CONTAINING PROTEIN 1; IFIH1","url":"https://www.omim.org/entry/606951"},{"mim_id":"606711","title":"SPECIFIC LANGUAGE IMPAIRMENT 1; SLI1","url":"https://www.omim.org/entry/606711"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Focal adhesion sites","reliability":"Supported"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":251.2}],"url":"https://www.proteinatlas.org/search/TM4SF20"},"hgnc":{"alias_symbol":["FLJ22800","TCCE518"],"prev_symbol":[]},"alphafold":{"accession":"Q53R12","domains":[{"cath_id":"1.20.120","chopping":"2-37_48-114_182-222","consensus_level":"medium","plddt":86.0458,"start":2,"end":222}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q53R12","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q53R12-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q53R12-F1-predicted_aligned_error_v6.png","plddt_mean":73.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TM4SF20","jax_strain_url":"https://www.jax.org/strain/search?query=TM4SF20"},"sequence":{"accession":"Q53R12","fasta_url":"https://rest.uniprot.org/uniprotkb/Q53R12.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q53R12/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q53R12"}},"corpus_meta":[{"pmid":"25310401","id":"PMC_25310401","title":"Sustained induction of collagen synthesis by TGF-β requires regulated intramembrane proteolysis of CREB3L1.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25310401","citation_count":52,"is_preprint":false},{"pmid":"23810381","id":"PMC_23810381","title":"TM4SF20 ancestral deletion and susceptibility to a pediatric disorder of early language delay and cerebral white matter hyperintensities.","date":"2013","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23810381","citation_count":42,"is_preprint":false},{"pmid":"27499293","id":"PMC_27499293","title":"Inverting the Topology of a Transmembrane Protein by Regulating the Translocation of the First Transmembrane Helix.","date":"2016","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/27499293","citation_count":37,"is_preprint":false},{"pmid":"32487748","id":"PMC_32487748","title":"Transcription factors activated through RIP (regulated intramembrane proteolysis) and RAT (regulated alternative translocation).","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32487748","citation_count":26,"is_preprint":false},{"pmid":"34540591","id":"PMC_34540591","title":"Study of rare genetic variants in TM4SF20, NFXL1, CNTNAP2, and ATP2C2 in Pakistani probands and families with language impairment.","date":"2021","source":"Meta gene","url":"https://pubmed.ncbi.nlm.nih.gov/34540591","citation_count":8,"is_preprint":false},{"pmid":"30808712","id":"PMC_30808712","title":"Identification of residues critical for topology inversion of the transmembrane protein TM4SF20 through regulated alternative translocation.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30808712","citation_count":5,"is_preprint":false},{"pmid":"36972171","id":"PMC_36972171","title":"Topological regulation of a transmembrane protein by luminal-to-cytosolic retrotranslocation of glycosylated sequence.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36972171","citation_count":3,"is_preprint":false},{"pmid":"32986129","id":"PMC_32986129","title":"Regulated Alternative Translocation: A Mechanism Regulating Transmembrane Proteins Through Topological Inversion.","date":"2021","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/32986129","citation_count":1,"is_preprint":false},{"pmid":"36711494","id":"PMC_36711494","title":"Global Transcriptomics of Congenital Hepatic Fibrosis in Autosomal Recessive Polycystic Kidney Disease using PCK rats.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/36711494","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":5671,"output_tokens":1636,"usd":0.020776},"stage2":{"model":"claude-opus-4-6","input_tokens":4877,"output_tokens":3903,"usd":0.18294},"total_usd":0.203716,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"TM4SF20 normally inhibits regulated intramembrane proteolysis (RIP) of the membrane-bound transcription factor CREB3L1; TGF-β stimulates collagen synthesis by inhibiting TM4SF20 expression, thereby releasing this inhibition and allowing CREB3L1 cleavage and nuclear entry.\",\n      \"method\": \"Loss-of-function and expression studies in human A549 cells; proteolytic activation assays of CREB3L1\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (expression knockdown, proteolysis assay, nuclear translocation) demonstrating TM4SF20 as inhibitor of CREB3L1 RIP\",\n      \"pmids\": [\"25310401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A 4 kb deletion removing exon 3 of TM4SF20 introduces a premature stop codon, producing a truncated protein that fails to target to the plasma membrane and instead accumulates in the cytoplasm, indicating that proper membrane targeting is required for TM4SF20 function.\",\n      \"method\": \"Minigene analysis, subcellular localization studies of truncated vs. wild-type TM4SF20\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiment with functional implication, single lab\",\n      \"pmids\": [\"23810381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Ceramide inverts the membrane topology of TM4SF20 by altering the translocation direction of its first transmembrane helix during translation (Regulated Alternative Translocation, RAT): in the absence of ceramide, the N terminus is translocated into the ER lumen (requiring TRAM2); in the presence of ceramide, the N terminus remains cytosolic in a TRAM2-independent manner. This topological inversion converts TM4SF20 from an inhibitor to an activator of CREB3L1 cleavage.\",\n      \"method\": \"Topology mapping assays, co-immunoprecipitation with TRAM2, ceramide treatment, TRAM2 knockdown, functional assays of CREB3L1 cleavage\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution of topological inversion with multiple orthogonal methods (topology assay, KD of TRAM2, ceramide treatment, protease cleavage readout), published in high-impact journal\",\n      \"pmids\": [\"27499293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Site-directed mutagenesis identified specific residues in the first transmembrane helix of TM4SF20 required for ceramide-induced RAT: Asn-26 in the GXXXN motif is essential and cannot be substituted even by Gln; Gly-22 can be replaced by Ala or Ser; Pro-29 together with Leu-25 or Val-17 form an additional critical surface. These residues are predicted to lie along the same face of the transmembrane helix, suggesting interactions with other proteins during translocation mediate RAT.\",\n      \"method\": \"Site-directed mutagenesis, TM4SF40-TM4SF20 chimera analysis, topology assays, functional CREB3L1 cleavage assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with chimera analysis and functional readout, multiple residues identified\",\n      \"pmids\": [\"30808712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TM4SF20 is synthesized in the ER with a cytosolic C terminus and a luminal loop before the last transmembrane helix that is N-glycosylated at N132, N148, and N163. In the absence of ceramide, the sequence surrounding glycosylated N163 undergoes retrotranslocation from ER lumen to cytosol (independent of ERAD), relocating the C terminus from cytosol to lumen. Ceramide delays this retrotranslocation, causing accumulation of the originally synthesized (non-retrotranslocated) form.\",\n      \"method\": \"N-glycosylation mapping, topology assays, ERAD inhibition, ceramide treatment, biochemical fractionation\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal biochemical methods (glycosylation mapping, topology assay, ERAD independence) in a single rigorous study\",\n      \"pmids\": [\"36972171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Ceramide-induced RAT of TM4SF20 is crucial for the effectiveness of doxorubicin-based chemotherapy, establishing a physiological role for TM4SF20 topological regulation in the cellular response to this chemotherapeutic agent.\",\n      \"method\": \"Cell-based chemotherapy response assays with RAT-deficient TM4SF20 mutants\",\n      \"journal\": \"Advances in experimental medicine and biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional loss-of-function with defined phenotypic readout, but reported in a review context with limited methodological detail\",\n      \"pmids\": [\"32986129\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TM4SF20 is a polytopic ER membrane protein whose topology is dynamically regulated by ceramide through Regulated Alternative Translocation (RAT): in the absence of ceramide, TRAM2-dependent translocation of its first transmembrane helix places the N terminus in the ER lumen, and subsequent retrotranslocation of a glycosylated luminal loop (around N163) further remodels topology; ceramide blocks both processes, inverting TM4SF20 topology and converting it from an inhibitor to an activator of CREB3L1 regulated intramembrane proteolysis, thereby controlling collagen synthesis and cellular responses to chemotherapy.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TM4SF20 is an ER-resident polytopic membrane protein that functions as a ceramide-responsive switch controlling regulated intramembrane proteolysis (RIP) of the transcription factor CREB3L1, thereby linking lipid signaling to collagen synthesis and chemotherapy responses. In the absence of ceramide, TM4SF20 adopts a TRAM2-dependent topology with its N terminus translocated into the ER lumen and undergoes post-translational retrotranslocation of a glycosylated luminal loop (N163 region), functioning as an inhibitor of CREB3L1 cleavage; TGF-β promotes collagen synthesis by downregulating TM4SF20 expression and relieving this inhibition [PMID:25310401, PMID:36972171]. Ceramide inverts TM4SF20 membrane topology through Regulated Alternative Translocation (RAT) of its first transmembrane helix—dependent on a critical GXXXN motif residue Asn-26—converting TM4SF20 from an inhibitor to an activator of CREB3L1 proteolytic activation, a mechanism also required for doxorubicin chemosensitivity [PMID:27499293, PMID:30808712, PMID:32986129]. Loss of exon 3 produces a truncated protein that fails to reach the membrane and accumulates in the cytoplasm, linking TM4SF20 to a language delay phenotype in affected families [PMID:23810381].\",\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"It was unknown whether TM4SF20 required intact membrane targeting for function; a disease-associated exon 3 deletion was shown to produce a truncated protein that mislocalizes to the cytoplasm, establishing that proper membrane insertion is essential.\",\n      \"evidence\": \"Minigene analysis and subcellular localization of truncated vs. wild-type TM4SF20 in transfected cells\",\n      \"pmids\": [\"23810381\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab observation without independent replication\", \"Whether cytoplasmic accumulation causes a dominant-negative effect or simple loss of function was not determined\", \"Downstream cellular consequences of mislocalization were not characterized\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"The molecular function of TM4SF20 was unknown; loss-of-function and expression studies revealed that TM4SF20 normally inhibits regulated intramembrane proteolysis of CREB3L1, and TGF-β stimulates collagen synthesis by downregulating TM4SF20 to release this inhibition.\",\n      \"evidence\": \"Knockdown, overexpression, CREB3L1 proteolytic activation, and nuclear translocation assays in A549 cells\",\n      \"pmids\": [\"25310401\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The mechanism by which TM4SF20 inhibits CREB3L1 cleavage (direct interaction vs. indirect) was not resolved\", \"Whether CREB3L1 is the sole downstream target was not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"How ceramide signaling could toggle TM4SF20 activity was unknown; topology mapping and TRAM2 dependence experiments demonstrated that ceramide inverts TM4SF20 membrane topology via Regulated Alternative Translocation (RAT), converting it from an inhibitor to an activator of CREB3L1 cleavage.\",\n      \"evidence\": \"Topology mapping, co-immunoprecipitation with TRAM2, TRAM2 knockdown, and ceramide treatment with CREB3L1 cleavage readout\",\n      \"pmids\": [\"27499293\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ceramide is sensed at the translocon to alter translocation directionality was not identified\", \"Whether other lipids can similarly trigger RAT was not explored\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"The structural determinants within TM4SF20 that sense ceramide during RAT were unknown; systematic mutagenesis identified Asn-26 in a GXXXN motif and an adjacent Pro-29/Leu-25/Val-17 surface on the first transmembrane helix as essential for ceramide-responsive topology inversion.\",\n      \"evidence\": \"Site-directed mutagenesis, TM4SF20-TM4SF40 chimera swaps, topology and CREB3L1 cleavage assays\",\n      \"pmids\": [\"30808712\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The translocon-side partner that reads these residues during RAT is unidentified\", \"No structural model of the TM1–translocon interaction exists\", \"Whether these residues directly contact ceramide or a ceramide-modified protein is unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Whether RAT of TM4SF20 had physiological consequences beyond collagen regulation was unclear; RAT-deficient mutants showed that ceramide-induced topology switching is required for doxorubicin chemosensitivity.\",\n      \"evidence\": \"Cell-based chemotherapy response assays with RAT-deficient TM4SF20 mutants\",\n      \"pmids\": [\"32986129\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Limited methodological detail in the reporting context\", \"In vivo validation of the chemotherapy connection is lacking\", \"Whether RAT affects sensitivity to other ceramide-generating chemotherapeutics is untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Post-translational topology remodeling of TM4SF20 beyond initial RAT was uncharacterized; glycosylation mapping revealed that a luminal loop glycosylated at N132/N148/N163 undergoes ERAD-independent retrotranslocation to the cytosol, and ceramide delays this second topology rearrangement.\",\n      \"evidence\": \"N-glycosylation site mapping, topology assays, ERAD inhibitor controls, ceramide treatment, biochemical fractionation\",\n      \"pmids\": [\"36972171\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The machinery mediating ERAD-independent retrotranslocation is unidentified\", \"Whether retrotranslocation is required for the inhibitory function of TM4SF20 has not been directly tested\", \"The fate of the deglycosylated retrotranslocated loop is unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The identity of the translocon component(s) that read ceramide levels and the TM1 GXXXN motif to execute RAT, and the structural basis of TM4SF20's dual topology, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No cryo-EM or crosslinking-MS structure of TM4SF20 at the translocon\", \"Direct ceramide-binding partner at the translocon not identified\", \"In vivo physiological roles beyond cell-based assays not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [2, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CREB3L1\", \"TRAM2\"],\n    \"other_free_text\": []\n  }\n}\n```\n\nWait, I need to fix the pathway entries - they should use Reactome IDs, not GO IDs. Let me reconsider.\n\n```json\n{\n  \"mechanistic_narrative\": \"TM4SF20 is an ER-resident polytopic membrane protein that functions as a ceramide-responsive switch controlling regulated intramembrane proteolysis (RIP) of the transcription factor CREB3L1, thereby linking lipid signaling to collagen synthesis and chemotherapy responses. In the absence of ceramide, TM4SF20 adopts a TRAM2-dependent topology with its N terminus translocated into the ER lumen and undergoes post-translational retrotranslocation of a glycosylated luminal loop (N163 region), functioning as an inhibitor of CREB3L1 cleavage; TGF-β promotes collagen synthesis by downregulating TM4SF20 expression and relieving this inhibition [PMID:25310401, PMID:36972171]. Ceramide inverts TM4SF20 membrane topology through Regulated Alternative Translocation (RAT) of its first transmembrane helix—dependent on a critical GXXXN motif residue Asn-26—converting TM4SF20 from an inhibitor to an activator of CREB3L1 proteolytic activation, a mechanism also required for doxorubicin chemosensitivity [PMID:27499293, PMID:30808712, PMID:32986129]. Loss of exon 3 produces a truncated protein that fails to reach the membrane and accumulates in the cytoplasm, linking TM4SF20 to a language delay phenotype in affected families [PMID:23810381].\",\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"It was unknown whether TM4SF20 required intact membrane targeting for function; a disease-associated exon 3 deletion was shown to produce a truncated protein that mislocalizes to the cytoplasm, establishing that proper membrane insertion is essential.\",\n      \"evidence\": \"Minigene analysis and subcellular localization of truncated vs. wild-type TM4SF20 in transfected cells\",\n      \"pmids\": [\"23810381\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab observation without independent replication\", \"Whether cytoplasmic accumulation causes a dominant-negative effect or simple loss of function was not determined\", \"Downstream cellular consequences of mislocalization were not characterized\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"The molecular function of TM4SF20 was unknown; loss-of-function and expression studies revealed that TM4SF20 normally inhibits regulated intramembrane proteolysis of CREB3L1, and TGF-β stimulates collagen synthesis by downregulating TM4SF20 to release this inhibition.\",\n      \"evidence\": \"Knockdown, overexpression, CREB3L1 proteolytic activation, and nuclear translocation assays in A549 cells\",\n      \"pmids\": [\"25310401\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The mechanism by which TM4SF20 inhibits CREB3L1 cleavage (direct interaction vs. indirect) was not resolved\", \"Whether CREB3L1 is the sole downstream target was not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"How ceramide signaling could toggle TM4SF20 activity was unknown; topology mapping and TRAM2 dependence experiments demonstrated that ceramide inverts TM4SF20 membrane topology via Regulated Alternative Translocation (RAT), converting it from an inhibitor to an activator of CREB3L1 cleavage.\",\n      \"evidence\": \"Topology mapping, co-immunoprecipitation with TRAM2, TRAM2 knockdown, and ceramide treatment with CREB3L1 cleavage readout\",\n      \"pmids\": [\"27499293\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ceramide is sensed at the translocon to alter translocation directionality was not identified\", \"Whether other lipids can similarly trigger RAT was not explored\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"The structural determinants within TM4SF20 that sense ceramide during RAT were unknown; systematic mutagenesis identified Asn-26 in a GXXXN motif and an adjacent Pro-29/Leu-25/Val-17 surface on the first transmembrane helix as essential for ceramide-responsive topology inversion.\",\n      \"evidence\": \"Site-directed mutagenesis, TM4SF20-TM4SF40 chimera swaps, topology and CREB3L1 cleavage assays\",\n      \"pmids\": [\"30808712\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The translocon-side partner that reads these residues during RAT is unidentified\", \"No structural model of the TM1–translocon interaction exists\", \"Whether these residues directly contact ceramide or a ceramide-modified protein is unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Whether RAT of TM4SF20 had physiological consequences beyond collagen regulation was unclear; RAT-deficient mutants showed that ceramide-induced topology switching is required for doxorubicin chemosensitivity.\",\n      \"evidence\": \"Cell-based chemotherapy response assays with RAT-deficient TM4SF20 mutants\",\n      \"pmids\": [\"32986129\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Limited methodological detail in the reporting context\", \"In vivo validation of the chemotherapy connection is lacking\", \"Whether RAT affects sensitivity to other ceramide-generating chemotherapeutics is untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Post-translational topology remodeling of TM4SF20 beyond initial RAT was uncharacterized; glycosylation mapping revealed that a luminal loop glycosylated at N132/N148/N163 undergoes ERAD-independent retrotranslocation to the cytosol, and ceramide delays this second topology rearrangement.\",\n      \"evidence\": \"N-glycosylation site mapping, topology assays, ERAD inhibitor controls, ceramide treatment, biochemical fractionation\",\n      \"pmids\": [\"36972171\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The machinery mediating ERAD-independent retrotranslocation is unidentified\", \"Whether retrotranslocation is required for the inhibitory function of TM4SF20 has not been directly tested\", \"The fate of the deglycosylated retrotranslocated loop is unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The identity of the translocon component(s) that read ceramide levels and the TM1 GXXXN motif to execute RAT, and the structural basis of TM4SF20's dual topology, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No cryo-EM or crosslinking-MS structure of TM4SF20 at the translocon\", \"Direct ceramide-binding partner at the translocon not identified\", \"In vivo physiological roles beyond cell-based assays not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [2, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [2, 4]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CREB3L1\", \"TRAM2\"],\n    \"other_free_text\": []\n  }\n}\n```"}